Abstract 48P
Background
Nav1.5 and nNav1.5 are potent metastatic markers for breast cancer with aggressive phenotype; detected in tumour tissues positive for lymph node metastasis. In vitro, most of the studies involving Nav1.5 and nNav1.5 were evaluated in monolayer cultured cells. Subsequently, since 3D-spheroid culture is now known for its ability to mimic multiple in vivo tumour microenvironment, there is a need to re-evaluate the potential role of Nav1.5 and nNav1.5 in a reliable tumour-accurate model. This study aimed to develop MDA-MB-231-3D-spheroid culture and assess the mRNA gene expression of Nav1.5 and nNav1.5 including several other potent markers for aggressive breast cancer, MMP1, MMP13 and fibronectin.
Methods
MDA-MB-231-3D-spheroids were cultured using scaffold-free liquid overlay method (via agarose layered 96-well flat bottomed plate) for 15 days. The total RNA was conventionally extracted and converted to cDNA. The mRNA expression for Nav1.5 and nNav1.5, MMP1, MMP13 and fibronectin were measured using real-time PCR and the expression were analysed via the 2-ΔΔCt method in which the monolayer culture was used as a normalizing control.
Results
MDA-MB-231-3D-spheroid was successfully developed. mRNA expression of Nav1.5, nNav1.5, MMP1 and fibronectin were significantly higher (p < 0.05) in MDA-MB-231-3D-spheroid compared to the monolayer culture; 4.8-fold, 2.1-fold, 62.1-fold and 5.3-fold, respectively.
Conclusions
Evaluating the role of tumour markers in a reliable tumour-accurate model is very important. MDA-MB-231-3D-spheroid was able to increase the expression of Nav1.5 and nNav1.5 and can be utilized to re-evaluate the role of Nav1.5 and nNav1.5 in cancer metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institute for Research in Molecular Medicine, Universiti Sains Malaysia.
Funding
Universiti Sains Malaysia, FRGS (203/CIPPM/6171212).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract
339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract